CING

Over the past six months, Cingulate reported its Q4 and full-year 2025 results, highlighting the acceptance of an NDA for CTx-1301 and strengthened intellectual property. The FDA accepted Cingulate's NDA for CTx-1301 and set a PDUFA date of May 31, 2026. The company announced a U.S. Notice of Allowance and additional European patent grants for CTx-1301. Cingulate closed a $12 million private placement to support its operations. Analyst ratings include maintained "Buy" recommendations from Ascendiant Capital and Roth Capital, with a consensus rating of "Hold" and an average price target of $34.50 as of May 9, 2026. Cingulate's stock price increased by 21.4% from January 1, 2026, to May 9, 2026, but decreased by 13.71% in the past month.